Tenaya Therapeutics’ (TNYA) Buy Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a $9.00 price target on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Tenaya Therapeutics in a report on Friday, April 25th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Tenaya Therapeutics has an average rating of “Moderate Buy” and an average price target of $6.25.

Tenaya Therapeutics Price Performance

Shares of NASDAQ TNYA opened at $0.67 on Thursday. Tenaya Therapeutics has a 12-month low of $0.36 and a 12-month high of $4.01. The company has a market capitalization of $109.02 million, a PE ratio of -0.70 and a beta of 3.01. The firm’s 50-day moving average is $0.67 and its two-hundred day moving average is $0.67.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.06. On average, analysts forecast that Tenaya Therapeutics will post -1.35 EPS for the current fiscal year.

Institutional Trading of Tenaya Therapeutics

Hedge funds have recently bought and sold shares of the company. Hsbc Holdings PLC acquired a new stake in Tenaya Therapeutics during the fourth quarter worth approximately $45,000. Northern Trust Corp raised its stake in Tenaya Therapeutics by 6.2% during the fourth quarter. Northern Trust Corp now owns 472,479 shares of the company’s stock worth $676,000 after purchasing an additional 27,632 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new position in Tenaya Therapeutics during the first quarter worth approximately $33,000. Deutsche Bank AG raised its stake in Tenaya Therapeutics by 304.1% during the fourth quarter. Deutsche Bank AG now owns 129,319 shares of the company’s stock worth $185,000 after purchasing an additional 97,318 shares during the period. Finally, Nuveen Asset Management LLC raised its stake in Tenaya Therapeutics by 25.2% during the fourth quarter. Nuveen Asset Management LLC now owns 345,192 shares of the company’s stock worth $494,000 after purchasing an additional 69,377 shares during the period. Institutional investors and hedge funds own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.